PI Industries margin stays 5.73 points below last year as revenue falls
Quarterly momentum improved, but a lower tax rate and other income cushioned the weak YoY operating result.
Filed 11 Aug 2026, 19:12 IST · after market close · P I Industries Ltd (PIIND)
Key takeaways
- Consolidated Q1FY27 revenue fell 10.43% YoY, while operating margin contracted 5.73 percentage points as expenses declined only 3.37%.
- Net profit rose 21.98% QoQ as the tax rate fell 9.27 percentage points, although other income accounted for 20.51% of pre-tax profit.
- Operating margin at 21.58% was 2.31 percentage points above the 19.27% median of 67 reporting sector peers.
Price around the results
Revenue recovered sequentially, but remained below last year
Consolidated revenue grew 8.76% QoQ, with expenses rising almost in line at 8.68%, supporting a 9.05% increase in operating profit. The YoY comparison was weaker: revenue fell 10.43%, while expenses declined only 3.37%, leading to a 29.22% drop in operating profit. Interest expense more than doubled YoY to pressure pre-tax profit further.
Tax relief and other income lifted reported profit
Net profit increased 21.98% QoQ even as pre-tax profit rose only 7.09%, because the tax rate fell 9.27 percentage points to 24.11%. Other income represented 20.51% of pre-tax profit, so reported earnings included a meaningful non-operating contribution. YoY net profit still fell 38.95%, with the tax rate 2.94 percentage points higher and operating profit down 29.22%.
Margins stabilised after a two-quarter slide
Operating margin edged up 0.06 percentage points QoQ to 21.58%, after falling from 28.91% in Q2FY26 to 21.97% in Q3 and 21.52% in Q4. The current margin remains 5.73 percentage points below Q1FY26. It was nevertheless 2.31 percentage points above the 19.27% median for 67 Commodities peers that had reported.
Expansion and overseas market activity remain management priorities
The presentation said the company is expanding and enhancing its GMP site in Lodi, Italy, and its non-GMP site in India. Management also said it is strengthening regulatory capabilities and ramping up market activity in Brazil, Mexico, Europe and the US. The company cited slower biotech funding and geopolitical challenges, while its presentation described a pipeline of more than 20 products at different development and registration stages.
The result was filed after market close; prior reactions were mostly negative
The results were filed after market close, so there was no market reaction to report yet. After the previous eight results, the stock fell seven times, with a median absolute move of 2.23%; the latest recorded moves included declines of 7.15% and 5.23%.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹1,702 cr | ₹1,565 cr | +8.76% | -10.43% |
| Other income | ₹66 cr | ₹74 cr | -10.81% | -25.59% |
| Expenses | ₹1,335 cr | ₹1,228 cr | +8.68% | -3.37% |
| Operating profit | ₹367 cr | ₹337 cr | +9.05% | -29.22% |
| Operating margin (%) | 21.58% | 21.52% | — | — |
| Interest | ₹8 cr | ₹4 cr | +113.51% | +102.56% |
| Depreciation | ₹104 cr | ₹107 cr | -2.81% | +7.46% |
| Profit before tax | ₹322 cr | ₹301 cr | +7.09% | -36.58% |
| Tax | ₹78 cr | ₹100 cr | -22.63% | -27.75% |
| Net profit | ₹244 cr | ₹200 cr | +21.98% | -38.95% |
| EPS (₹) | ₹16.10 | ₹13.20 | +21.97% | -38.95% |
Operating margin of 21.58% compares with a Commodities sector median of 19.27% across 67 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Expansion
- The company is expanding and enhancing its GMP site in Lodi, Italy, and its non-GMP site in India.
New products
- The innovation pipeline contains more than 20 products at different development and registration stages.
- The newly registered PHC949 is being tested in the US.
New initiatives
- PIHS is strengthening regulatory capabilities to become best-in-class.
- The company is ramping up market activities in Brazil, Mexico, Europe and the US.
- The company is strengthening relationships with key influencers and stakeholders.
Problems & risks
- PIHS cited a slowdown in biotech funding and geopolitical challenges.
What to watch
- Whether operating margin holds above 21.58% after the two-quarter decline from 28.91%.
- Whether quarterly revenue growth remains above the 8.76% QoQ recorded in Q1FY27.
- Whether other income remains near 20.51% of pre-tax profit and the tax rate near 24.11%.